Investigational drug · Phase 2
Verekitug
Also called: UPB-101
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Severe Asthma, Chronic Obstructive Pulmonary Disease, Chronic Rhinosinusitis With Nasal Polyps.
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
4
2 still active
All registered trials
4
Any phase or sponsor naming "Verekitug"
First trial start
2023
Dec 18, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Verekitug", any sponsor or status.
Conditions studied
As listed on its trial records.
- Severe Asthma
- Chronic Obstructive Pulmonary Disease
- Chronic Rhinosinusitis With Nasal Polyps
Approved drugs for the same conditions: Asthma · COPD · Respiratory
Largest trials
Live from ClinicalTrials.gov: studies naming "Verekitug" as an intervention, largest first.
- A Study to Assess the Efficacy and Safety of Verekitug in Participants With COPDPivotal-lookingActive, not recruiting
Upstream Bio Inc.Industry
NCT06981078 · 666 participants (planned) · Start Jul 2, 2025 · Primary completion Oct 2027
Drug: Verekitug · For: Chronic Obstructive Pulmonary Disease
Sites: Bakersfield, California; Encino, California; Lomita, California · 242 sites in all
- A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALIANT)Pivotal-lookingCompleted
Upstream Bio Inc.Industry
NCT06196879 · 479 participants · Start Feb 27, 2024 · Primary completion Dec 16, 2025
Drug: Verekitug (UPB-101); Placebo · For: Severe Asthma
Sites: Birmingham, Alabama; Bakersfield, California; Los Angeles, California · 155 sites in all
- A Long-Term Safety and Efficacy Study of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALOUR)Pivotal-lookingActive, not recruiting
Upstream Bio Inc.Industry
NCT06966479 · 396 participants · Start May 21, 2025 · Primary completion Sep 2027
Drug: Verekitug; Placebo · For: Severe Asthma
Sites: Bakersfield, California; Northridge, California; Upland, California · 102 sites in all
Upstream Bio Inc.Industry
NCT06164704 · 81 participants · Start Dec 18, 2023 · Primary completion Jul 7, 2025
Drug: Verekitug (UPB-101); Placebo · For: Chronic Rhinosinusitis With Nasal Polyps
Sites: Los Angeles, California; Newport Beach, California; Roseville, California · 41 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Lessons learned from clinical trials of thymic stromal lymphopoietin inhibition.
Corren J, Borish L, Brightling C, et al. · J Allergy Clin Immunol 2026
- Verekitug, a Novel Antibody Antagonist to the TSLP Receptor in Adults with Asthma: A 32-Week Randomized Phase 1b Multiple Ascending-Dose Trial.
Singh D, Brickman CM, Lloyd P, et al. · Clin Pharmacol Ther 2026
- Biologic Therapies for Severe Asthma: Current Insights and Future Directions.
Faria N, Costa MI, Fernandes AL, et al. · J Clin Med 2025
- Investigational thymic stromal lymphopoietin inhibitors for the treatment of asthma: a systematic review.
Rogliani P, Manzetti GM, Bettin FR, et al. · Expert Opin Investig Drugs 2024
Also in development for Severe Asthma
- TQC2731Phase 35 trials
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. · Asthma, Chronic Obstructive Pulmonary Disease, Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
- GB-0895Phase 32 trials
Generate Biomedicines · Severe Asthma
- FB704APhase 21 trial
Oneness Biotech Co., Ltd. · Severe Asthma
- FrevecitinibPhase 21 trial
Kinaset Therapeutics Inc · Severe Asthma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.